METabolic EXplorer's share price fell by 14% following the signature, on December 23, of an agreement with its main partners securing the liquidity required to implement its strategy and its 2023-2024 industrial transformation plan.

This agreement includes new financing to enable the company to immediately undertake the initial investments required, in particular to boost its sales force and gradually resume production at the Amiens plant.

The agreement, which remains subject to certain conditions precedent, includes a capital increase of up to eight million euros, at a unit subscription price of 1.13 euros, with a commitment from the SPI fund.

Assuming a gradual recovery in business, MetEx is targeting a cautious 2023 financial year, with consolidated sales of around 275 million euros and consolidated EBITDA between -8 million euros and breakeven.

Copyright (c) 2022 CercleFinance.com. All rights reserved.